Previous close | 9.18 |
Open | 9.18 |
Bid | 9.32 x 100 |
Ask | 9.40 x 100 |
Day's range | 9.15 - 9.36 |
52-week range | 7.51 - 12.44 |
Volume | |
Avg. volume | 161,462 |
Market cap | 430.825M |
Beta (5Y monthly) | 0.73 |
PE ratio (TTM) | 25.27 |
EPS (TTM) | 0.37 |
Earnings date | 25 Apr 2024 - 29 Apr 2024 |
Forward dividend & yield | 0.32 (3.49%) |
Ex-dividend date | 09 Apr 2024 |
1y target est | 12.25 |
Edwards Lifesciences, DexCom and STERIS have been highlighted in this Industry Outlook article.
The Zacks Medical - Instruments industry is expected to gain from the rising adoption of smart healthcare options, including genAI. However, supply issues and staffing shortages continue to disrupt growth. EW, DXCM and STE appear well-poised to brave the challenges.
The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.